1. Home
  2. IMCC vs SNGX Comparison

IMCC vs SNGX Comparison

Compare IMCC & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCC
  • SNGX
  • Stock Information
  • Founded
  • IMCC 1980
  • SNGX 1987
  • Country
  • IMCC Israel
  • SNGX United States
  • Employees
  • IMCC N/A
  • SNGX N/A
  • Industry
  • IMCC Medicinal Chemicals and Botanical Products
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMCC Health Care
  • SNGX Health Care
  • Exchange
  • IMCC Nasdaq
  • SNGX Nasdaq
  • Market Cap
  • IMCC 7.5M
  • SNGX 7.4M
  • IPO Year
  • IMCC N/A
  • SNGX 1987
  • Fundamental
  • Price
  • IMCC $2.19
  • SNGX $2.32
  • Analyst Decision
  • IMCC
  • SNGX
  • Analyst Count
  • IMCC 0
  • SNGX 0
  • Target Price
  • IMCC N/A
  • SNGX N/A
  • AVG Volume (30 Days)
  • IMCC 16.0K
  • SNGX 618.6K
  • Earning Date
  • IMCC 03-27-2025
  • SNGX 03-14-2025
  • Dividend Yield
  • IMCC N/A
  • SNGX N/A
  • EPS Growth
  • IMCC N/A
  • SNGX N/A
  • EPS
  • IMCC N/A
  • SNGX N/A
  • Revenue
  • IMCC $38,042,859.00
  • SNGX $364,183.00
  • Revenue This Year
  • IMCC $22.59
  • SNGX N/A
  • Revenue Next Year
  • IMCC $32.86
  • SNGX $76.64
  • P/E Ratio
  • IMCC N/A
  • SNGX N/A
  • Revenue Growth
  • IMCC N/A
  • SNGX N/A
  • 52 Week Low
  • IMCC $1.50
  • SNGX $1.83
  • 52 Week High
  • IMCC $8.10
  • SNGX $14.88
  • Technical
  • Relative Strength Index (RSI)
  • IMCC 53.35
  • SNGX 36.12
  • Support Level
  • IMCC $2.05
  • SNGX $2.23
  • Resistance Level
  • IMCC $2.60
  • SNGX $2.39
  • Average True Range (ATR)
  • IMCC 0.21
  • SNGX 0.17
  • MACD
  • IMCC 0.02
  • SNGX 0.01
  • Stochastic Oscillator
  • IMCC 58.31
  • SNGX 22.12

About IMCC IM Cannabis Corp.

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: